
TY  - JOUR
TI  - Abstracts of papers, Ninety-eighth Annual Meeting, The Town and Country Hotel San Diego, California, March 5–8, 1997**
JO  - Clinical Pharmacology & Therapeutics
JA  - Clinical Pharmacology & Therapeutics
VL  - 61
IS  - 2
SN  - 0009-9236
UR  - https://doi.org/10.1016/S0009-9236(97)90074-6b
DO  - doi:10.1016/S0009-9236(97)90074-6b
SP  - 137
EP  - 236
PY  - 1997
AB  - Clinical Pharmacology  doi:
ER  - 

TY  - JOUR
TI  - Podium Presentation Abstracts
JO  - BJU International
JA  - BJU Int
VL  - 113
IS  - S4
SN  - 1464-4096
UR  - https://doi.org/10.1111/bju.12618
DO  - doi:10.1111/bju.12618
SP  - 1
EP  - 50
PY  - 2014
ER  - 

TY  - JOUR
TI  - Abstracts and Index of Authors
JO  - Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
VL  - 25
IS  - 10
SN  - 0277-0008
UR  - https://doi.org/10.1592/phco.2005.25.10.1431
DO  - doi:10.1592/phco.2005.25.10.1431
SP  - 1431
EP  - 1551
PY  - 2005
ER  - 

TY  - JOUR
AU  - Previsdomini, Marco
AU  - Graziano, Elisa
AU  - Decosterd, Laurent
AU  - Courlet, Perrine
AU  - Perren, Andreas
AU  - Ceschi, Alessandro
C8  - LET-00101-19.R1
TI  - Severe rosuvastatin accumulation with rhabdomyolysis due to drug interactions and low cardiac output syndrome
JO  - British Journal of Clinical Pharmacology
JA  - Br J Clin Pharmacol
VL  - 85
IS  - 7
SN  - 0306-5251
UR  - https://doi.org/10.1111/bcp.13950
DO  - doi:10.1111/bcp.13950
SP  - 1616
EP  - 1618
PY  - 2019
ER  - 

TY  - JOUR
TI  - Scientific Abstracts and Sessions
JO  - Medical Physics
JA  - Med. Phys.
VL  - 45
IS  - 6
SN  - 0094-2405
UR  - https://doi.org/10.1002/mp.12938
DO  - doi:10.1002/mp.12938
SP  - e120
EP  - e706
PY  - 2018
ER  - 

TY  - JOUR
TI  - 2011 ACCP Annual Meeting
JO  - Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
VL  - 31
IS  - 10
SN  - 0277-0008
UR  - https://doi.org/10.1592/phco.31.10.311e
DO  - doi:10.1592/phco.31.10.311e
SP  - 311e
EP  - 453e
PY  - 2011
ER  - 

TY  - JOUR
TI  - Abstracts from the Scandinavian Society of Anesthesiology and Intensive Care Medicine 34th Congress
JO  - Acta Anaesthesiologica Scandinavica
JA  - Acta Anaesthesiol. Scand.
VL  - 61
IS  - 8
SN  - 0001-5172
UR  - https://doi.org/10.1111/aas.12941
DO  - doi:10.1111/aas.12941
SP  - 962
EP  - 1062
PY  - 2017
ER  - 

TY  - JOUR
AU  - Chastre, J.
AU  - Blasi, F.
AU  - Masterton, R. G.
AU  - Rello, J.
AU  - Torres, A.
AU  - Welte, T.
TI  - European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid
JO  - Clinical Microbiology and Infection
JA  - Clin Microbiol Infect
VL  - 20
IS  - s4
SN  - 1198-743X
UR  - https://doi.org/10.1111/1469-0691.12450
DO  - doi:10.1111/1469-0691.12450
SP  - 19
EP  - 36
KW  - Clinical management
KW  - Europe
KW  - linezolid
KW  - methicillin-resistant Staphylococcus aureus
KW  - nosocomial pneumonia
KW  - ventilator-associated pneumonia
PY  - 2014
AB  - Abstract Methicillin-resistant Staphylococcus aureus (MRSA) is an important cause of antimicrobial-resistant hospital-acquired infections worldwide and remains a public health priority in Europe. Nosocomial pneumonia (NP) involving MRSA often affects patients in intensive care units with substantial morbidity, mortality and associated costs. A guideline-based approach to empirical treatment with an antibacterial agent active against MRSA can improve the outcome of patients with MRSA NP, including those with ventilator-associated pneumonia. New methods may allow more rapid or sensitive diagnosis of NP or microbiological confirmation in patients with MRSA NP, allowing early de-escalation of treatment once the pathogen is known. In Europe, available antibacterial agents for the treatment of MRSA NP include the glycopeptides (vancomycin and teicoplanin) and linezolid (available as an intravenous or oral treatment). Vancomycin has remained a standard of care in many European hospitals; however, there is evidence that it may be a suboptimal therapeutic option in critically ill patients with NP because of concerns about its limited intrapulmonary penetration, increased nephrotoxicity with higher doses, as well as the emergence of resistant strains that may result in increased clinical failure. Linezolid has demonstrated high penetration into the epithelial lining fluid of patients with ventilator-associated pneumonia and shown statistically superior clinical efficacy versus vancomycin in the treatment of MRSA NP in a phase IV, randomized, controlled study. This review focuses on the disease burden and clinical management of MRSA NP, and the use of linezolid after more than 10 years of clinical experience.
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - International Journal of Laboratory Hematology
JA  - Int. Jnl. Lab. Hem.
VL  - 38
IS  - S2
SN  - 1751-5521
UR  - https://doi.org/10.1111/ijlh.12567
DO  - doi:10.1111/ijlh.12567
SP  - 1
EP  - 119
PY  - 2016
ER  - 

TY  - JOUR
TI  - SARS abstracts
JO  - BJS (British Journal of Surgery)
JA  - Br J Surg
VL  - 102
IS  - s5
SN  - 0007-1323
UR  - https://doi.org/10.1002/bjs.9822
DO  - doi:10.1002/bjs.9822
SP  - 3
EP  - 52
PY  - 2015
ER  - 

TY  - JOUR
AU  - Sawers, Andrew
AU  - Hafner, Brian J.
TI  - Using Clinical Balance Tests to Assess Fall Risk among Established Unilateral Lower Limb Prosthesis Users: Cutoff Scores and Associated Validity Indices
JO  - PM&R
JA  - Journal of Injury, Function and Rehabilitation
VL  - 12
IS  - 1
SN  - 1934-1482
UR  - https://doi.org/10.1002/pmrj.12160
DO  - doi:10.1002/pmrj.12160
SP  - 16
EP  - 25
PY  - 2020
AB  - Background Clinicians are routinely required to make decisions about fall risk among lower limb prosthesis (LLP) users. These decisions can be guided by standardized clinical balance tests but require population- and test-specific cutoff scores and validity indices to categorize individuals as probable fallers or nonfallers on the basis of test performance. Despite the importance of cutoff scores and validity indices to clinical interpretation of clinical balance test scores, they are rarely reported for LLP users. In their absence, clinicians cannot use results from clinical balance tests to assess the likelihood of a fall by any one patient. Objective Derive cutoff scores, and associated validity indices, for clinical balance tests administered to established unilateral LLP users. Design Cross-sectional study. Setting Outpatient clinic and research laboratory. Participants Established ambulatory unilateral transtibial and transfemoral prosthesis users (n?=?40). Intervention Not applicable. Main Outcome Measure(s) Optimal cutoff scores and related validity indices (ie, area under the curve, sensitivity, specificity, likelihood ratios) were computed for five balance tests, the activities-specific balance confidence scale (ABC), timed up and go (TUG), four square step test (FSST), Berg balance scale (BBS), and narrowing-beam walking test (NBWT). Results Cutoff scores were identified for the NBWT (≤.43/1.0), TUG (≥8.17?seconds], FSST (≥8.49 seconds), BBS (≤50.5/56), and ABC (≤80.2/100). Validity indices (ie, area under the curve, sensitivity, specificity, and likelihood ratios) for the NBWT, TUG, and FSST had greater diagnostic accuracy and provided more information about the probability of a fall than those for the BBS or ABC. Conclusion Performance above or below identified cutoff scores for the NBWT, FSST, and TUG provides information about potentially important shifts in the probability of falling among established unilateral LLP users. These results can serve as initial benchmarks to reduce uncertainty surrounding fall risk assessment in established unilateral LLP users but require future prospective evaluation. Level of Evidence III
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Anaesthesia
JA  - Anaesthesia
VL  - 70
IS  - S3
SN  - 0003-2409
UR  - https://doi.org/10.1111/anae.13136
DO  - doi:10.1111/anae.13136
SP  - 11
EP  - 101
PY  - 2015
ER  - 

TY  - JOUR
AU  - American College of Clinical Pharmacy
TI  - Cincinnati Convention Center Hyatt Regency Cincinnati Cincinnati, Ohio
JO  - Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
VL  - 18
IS  - 5
SN  - 0277-0008
UR  - https://doi.org/10.1002/j.1875-9114.1998.tb03946.x
DO  - doi:10.1002/j.1875-9114.1998.tb03946.x
SP  - 1138
EP  - 1177
PY  - 1998
ER  - 

TY  - JOUR
TI  - Poster Presentations
JO  - Mycoses
VL  - 52
IS  - s1
SN  - 0933-7407
UR  - https://doi.org/10.1111/j.1439-0507.2009.01782.x
DO  - doi:10.1111/j.1439-0507.2009.01782.x
SP  - 29
EP  - 123
PY  - 2009
ER  - 

TY  - JOUR
TI  - Thursday 17 October 2019
JO  - Journal of Medical Imaging and Radiation Oncology
JA  - J Med Imaging Radiat Oncol
VL  - 63
IS  - S1
SN  - 1754-9477
UR  - https://doi.org/10.1111/1754-9485.12954
DO  - doi:10.1111/1754-9485.12954
SP  - 4
EP  - 21
PY  - 2019
ER  - 

TY  - JOUR
TI  - Abstracts of papers,** Ninetieth Annual Meeting, March 8–10, 1989 Opryland Hotel, Nashville, Tennessee
JO  - Clinical Pharmacology & Therapeutics
JA  - Clinical Pharmacology & Therapeutics
VL  - 45
IS  - 2
SN  - 0009-9236
UR  - https://doi.org/10.1038/clpt.1989.17
DO  - doi:10.1038/clpt.1989.17
SP  - 121
EP  - 190
PY  - 1989
AB  - Clinical Pharmacology and Therapeutics (1989) 45, 121?190; doi:10.1038/clpt.1989.17
ER  - 

TY  - JOUR
TI  - Moderated Poster
JO  - International Journal of Urology
JA  - Int. J. Urol.
VL  - 25
IS  - S1
SN  - 0919-8172
UR  - https://doi.org/10.1111/iju.13751
DO  - doi:10.1111/iju.13751
SP  - 245
EP  - 375
PY  - 2018
ER  - 

TY  - JOUR
TI  - E-Posters
JO  - BJS (British Journal of Surgery)
JA  - Br J Surg
VL  - 104
IS  - S6
SN  - 0007-1323
UR  - https://doi.org/10.1002/bjs.10634
DO  - doi:10.1002/bjs.10634
SP  - 83
EP  - 243
PY  - 2017
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - BJU International
JA  - BJU Int
VL  - 116
IS  - S2
SN  - 1464-4096
UR  - https://doi.org/10.1111/bju.13221
DO  - doi:10.1111/bju.13221
SP  - 18
EP  - 38
PY  - 2015
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Journal of Thrombosis and Haemostasis
JA  - J Thromb Haemost
VL  - 14
IS  - S1
SN  - 1538-7933
UR  - https://doi.org/10.1111/jth.13325
DO  - doi:10.1111/jth.13325
SP  - 1
EP  - 168
PY  - 2016
ER  - 
